Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06265727 | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | PHASE1/PHASE2 | RECRUITING | 348 | — | — | Mar 1, 2024 | Jan 1, 2027 | Jan 7, 2026 | - | — |
| Name | Type | Description |
|---|---|---|
| CRB-701 | DRUG | Nectin-4 targeted Antibody Drug Conjugate (ADC) |
| Anti-PD-1 | DRUG | checkpoint inhibitor |